Abstract
Haemophilia affects more than 184,000 people worldwide.1 Despite increasing advances, it is still associated with a high prevalence of disabilities, posing an economic burden to individuals and health systems.2 Over the last decades, significant therapeutic improvements have been achieved, including advances in blood safety, prophylaxis with coagulation factor concentrates (CFC), treatment with inhibitors of coagulation factors, orthopedic surgeries to correct limbs deformities and long-acting CFC.2,3 It is anticipated that new compounds which could be applied subcutaneously and gene therapy will be of benefit to patients with hemophilia (PWH) in the future.4